University of Pittsburgh School of Medicine scientists have isolated a biomolecule that “completely and specifically” neutralizes the virus that causes coronavirus, according to a report published Monday in the journal Cell. The antibody component is 10 times smaller than a full-sized antibody and has been used to create a drug known as Ab8 for use as a therapeutic and preventative against SARS-CoV-2. It is is “highly effective” in preventing and treating SARS-CoV-2 infection in mice and hamsters. The drug is seen as a potential preventative against SARS-CoV-2. The drug does not bind to human cells, which suggests it will not have negative side-effects in people. Ab8 not only has potential as therapy for COVID-19, but it also could be used to keep people from getting SARS-CoV-2 infections,” said co-author John Mellors, chief of the Division of Infectious Diseases at Pitt and UPMC.
The drug may be able to be inhaled or administred through a superficial injection, instead of an IV. The medival world is expected to engage to study the new drug, urging to make it the possible solution in the battle with the dangerous virus. For the instant no other information regarding how the new drug can be mass produced were given.